With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Asia, Pacifi c Rim countries.
The latest business developments from across Asia by Gwyneth Astles To appear in our next issue, send your Business and Financial News stories to
gwyneth@intlabmate.com
This section of International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising
potential for other companies to move into export markets.
Reseller partnership expands proteomics access
SCIEX, a global leader in life science analytical technologies and Danaher company, has signed a reseller agreement with Evosep Biosystems, a specialist in proteomics workfl ows. This collaboration makes SCIEX mass spectrometry systems available alongside the Evosep Eno platform, delivering a streamlined LC-MS solution designed for pharmaceutical and biotech research.
Combining SCIEX’s advanced MS technology with Evosep’s high-throughput sample separation, the partnership supports large-scale proteomics studies with improved peptide and protein identifi cations. Recent data shows a 5-fold increase in peptide precursors and a 3-fold increase in protein groups when coupling Evosep Eno with the ZenoTOF 8600 system at 500 samples per day.
Available in North America and much of Europe, the integrated solution will be offered through SCIEX’s unifi ed product catalogue, with Evosep providing UHPLC service and support.
“Our partnership with Evosep delivers powerful, standardised proteomics solutions tailored for pharma and biotech,” said Jose Castro-Perez, VP of Product Management at SCIEX. “Together, we help researchers accelerate discovery with greater speed and precision.”
More information online:
ilmt.co/PL/KwKj 64955pr@reply-direct.com
Exclusive partnership expands access to single-cell analysis in China
Strategic diagnostics expansion into Greece
Sysmex has announced the establishment of a new wholly owned subsidiary, Sysmex Greece IKE, as part of its strategic plan to enhance direct sales, customer care, and business development in Southern Europe.
Sysmex has had a presence in Greece for over 30 years through partnerships and distributors. The decision to establish a local subsidiary marks a signifi cant step in strengthening its European business infrastructure and aligning its operations more closely with customer needs in the region.
The new entity will enable Sysmex to offer direct sales and high-quality, standardised customer support in key diagnostic fi elds, including haemostasis, urinalysis, clinical fl ow cytometry (FCM), and life sciences.
By delivering value-added solutions tailored to local market characteristics, Sysmex aims to reinforce its position in existing markets while laying the groundwork for expansion into emerging segments.
Greece’s healthcare system, underpinned by universal health insurance, is poised for growth amid demographic
changes and a recovering economy. Sysmex sees this as an opportunity to provide advanced diagnostics and support improved patient outcomes in collaboration with local stakeholders.
“Establishing Sysmex Greece .KE refl ects our commitment to deepening relationships with healthcare providers in the region,” said Kaoru Asano, President of Sysmex Corporation. “By strengthening our direct operations, we can better understand local challenges, deliver tailored solutions, and contribute meaningfully to the advancement of healthcare in Greece and beyond.”
This latest move follows a long-standing strategy by Sysmex to expand its footprint across Europe, dating back to its fi rst European subsidiary in Germany in 1980. The company plans to continue investing in regional capabilities and cross-border synergies to accelerate innovation and access in diagnostics.
More information online:
ilmt.co/PL/Rw8L 65018pr@reply-direct.com
Strategic acquisition targets Turkish pharma growth
EarlyHealth Group, a leading global pharmaceutical service provider, has announced the acquisition of Corena Ecza Deposu, Turkey’s foremost pharmaceutical distributor. This move signifi cantly expands EarlyHealth’s presence in the Turkish life sciences market and supports its ambitious $100 million growth strategy aimed at internationalising Türkiye’s pharmaceutical sector.
The acquisition merges Corena’s deep national expertise with EarlyHealth’s global platform, accelerating government-backed export initiatives and boosting collaboration between academia and industry. It also enhances Turkey’s role in clinical research and pharmaceutical innovation.
Dr Dan A Renout, CEO of EarlyHealth Group, commented: “Combining forces with Corena positions us to advance Turkey’s pharmaceutical export capabilities and foster innovation through strengthened partnerships. This
acquisition aligns with our vision to support sustainable growth in emerging life sciences markets.”
Mrs Nihal Aygün, Corena’s owner, said: “Our long-standing partnership with EarlyHealth now reaches a new milestone. Together, we’re committed to reducing Turkey’s reliance on pharmaceutical imports and elevating the country’s status in the global supply chain.”
The signing ceremony took place in Dubai, attended by prominent fi gures including His Excellency Onur Saylan, Consul General of Türkiye, and members of the Abu Dhabi Royal Family, highlighting the strategic importance of the partnership for cross-border healthcare innovation and investment.
More information online:
ilmt.co/PL/o8JJ 64970pr@reply-direct.com
L-R: Johnathan Fu (Sphere Bio), Dale Levitzke (Sphere Bio), Wei Zhang (Redbert Biotechnology). Credit: Sphere Bio
Sphere Bio has announced a major step forward in its Asia- Pacifi c expansion strategy by appointing Redbert Biotechnology as its exclusive distribution partner in China. The collaboration is set to increase access to the company’s picodroplet-based single-cell analysis platforms, including the recently launched Cyto-Mine® Chroma multiplexing system.
The agreement aims to meet rising demand in the Chinese market for advanced tools supporting antibody discovery, cell line development, and cell therapy research. Redbert Biotechnology brings a strong regional footprint, with offi ces across major Chinese cities, and extensive experience working with CDMOs, CROs, and academic institutions.
To support this growth, Sphere Bio has also appointed Johnathan Fu as China Distribution Manager. With nearly two decades of experience in life science instrumentation sales – including roles at 10x Genomics, Roche Diagnostics, and Bio-Rad – Fu will lead local commercial strategy and customer support. He reports to Jay Manikandan, Sphere Bio’s VP of Commercial for APAC.
Dale Levitzke, CEO of Sphere Bio, said: “China is a key market for innovation in life sciences. This partnership, along with our regional expansion efforts, ensures we can better serve researchers with cutting-edge solutions and dedicated local support.”
Wei Zhang, CEO of Redbert Biotechnology, added: “We are excited to introduce Sphere Bio’s technology to our customers, particularly the Cyto-Mine Chroma platform. It has the potential to signifi cantly advance research across the region.”
Johnathan Fu, China Distribution Manager, added: “I’m excited to help bring Sphere Bio’s technology to more researchers in China. Our goal is to make adoption seamless and ensure customers get the support they need to accelerate discovery.”
More information online:
ilmt.co/PL/px6B 65063pr@reply-direct.com
Does your company sell or wish to sell laboratory products and services to the economies of Asia? Are you looking for local distributors and agents to represent you?
If so, why not advertise your products in our market-leading journal Lab Asia.
Email:
info@intlabmate.com
Business
Opportunities Asia
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
